Information  X 
Enter a valid email address

Oxford Biomedica PLC (OXB)

  Print   

Thursday 16 April, 2020

Oxford Biomedica PLC

Notice of Results Update

RNS Number : 9325J
Oxford Biomedica PLC
16 April 2020
 

 

 

Notice of Results Update

 

Full Year Results to be Published on 6th May 2020

 

Oxford, UK - 16th April, 2020: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announces today that, following guidance from the Financial Reporting Council (FRC) and Financial Conduct Authority (FCA) in relation to the ongoing Covid-19 pandemic, the Group has elected to delay the release of its audited final results in order to take the time to more clearly assess the possible future impact of Covid-19 on its disclosures and forward looking statements.

 

The Group's results for the year ending 31st December 2019 will now be published on 6th May 2020, as opposed to 23rd April 2020 as had been previously announced. This new date is in accordance with the FCA's recent statement of policy allowing companies an extra two months to publish their audited financial results.

 

The Group confirms that the business update issued on 18th March 2020 still remains current with Revenues for the year of c.£65 million and a low single digit operating EBITDA loss in the second half of 2019.

 

 

 

 

-Ends-

Enquiries:

 

 

Oxford Biomedica plc

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Catherine Isted, Head of Corporate Development & IR

 

 

 

 

T: +44 (0)1865 783 000

T: +44 (0)1865 783 000

T: +44 (0)1865 954 161 / E: [email protected]

 

 

Consilium Strategic Communications

 

Mary-Jane Elliott/Matthew Neal

 

 

 

T: +44 (0)20 3709 5700

 

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at www.oxb.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORFLFLSSSIRLII

a d v e r t i s e m e n t